Secretion and Biological Activity of Short Signal Peptide IL-15 is Chaperoned by IL-15 Receptor Alpha in Vivo

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2009 Aug 22

PMID 19696432

Citations 28

Authors

Cristina Bergamaschi

Rashmi Jalah

Viraj Kulkarni

Margherita Rosati

Gen-Mu Zhang

Candido Alicea

Andrei S Zolotukhin

Barbara K Felber

George N Pavlakis

Affiliations

Soon will be listed here.

Abstract

The two known isoforms of IL-15 contain either a long signal peptide (LSP) or a short signal peptide (SSP), and are produced by alternatively spliced transcripts. It has been proposed that SSP IL-15 remains exclusively intracellular, and its function is unclear. In this study, we show that, similar to LSP IL-15, the SSP IL-15 is stabilized and secreted efficiently upon coexpression of IL-15Ralpha. Coinjection of SSP IL-15- and IL-15Ralpha-expressing plasmids into mice resulted in increased plasma levels of bioactive heterodimeric IL-15 and mobilization and expansion of NK and T cells. Therefore, SSP IL-15 is secreted and bioactive when produced as a heterodimer with IL-15Ralpha in the same cell. The apparent t(1/2) of this heterodimer is lower compared with LSP IL-15/IL-15Ralpha, due to different intracellular processing. Coexpression of both LSP IL-15 and SSP IL-15 in the presence of IL-15Ralpha results in lower levels of bioactive IL-15, indicating that LSP and SSP IL-15 compete for the binding to IL-15Ralpha when expressed in the same cell. Because the SSP IL-15 interaction to IL-15Ralpha leads to a complex with lower apparent stability, SSP IL-15 functions as competitive inhibitor of LSP IL-15. The data suggest that usage of alternative splicing is an additional level of control of IL-15 activity. Expression of both SSP and LSP forms of IL-15 appears to be conserved in many mammals, suggesting that SSP may be important for expressing a form of IL-15 with lower magnitude or duration of biological effects.

Citing Articles

IL-15 transpresentation by ovarian cancer cells improves CD34 progenitor-derived NK cell's anti-tumor functionality.

Vidal-Manrique M, Nieuwenstein T, Hooijmaijers L, de Jonge P, Djojoatmo M, Jansen J Oncoimmunology. 2025; 14(1):2465010.

PMID: 39960378 PMC: 11834524. DOI: 10.1080/2162402X.2025.2465010.

Profibrogenic role of IL-15 through IL-15 receptor alpha-mediated trans-presentation in the carbon tetrachloride-induced liver fibrosis model.

Cloutier M, Variya B, Akbari S, Rexhepi F, Ilangumaran S, Ramanathan S Front Immunol. 2024; 15:1404891.

PMID: 38919611 PMC: 11196400. DOI: 10.3389/fimmu.2024.1404891.

Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy.

Hu S, Meng K, Wang T, Qu R, Wang B, Xi Y Biomark Res. 2024; 12(1):40.

PMID: 38637902 PMC: 11027539. DOI: 10.1186/s40364-024-00586-w.

Signalling mechanisms driving homeostatic and inflammatory effects of interleukin-15 on tissue lymphocytes.

Skariah N, James O, Swamy M Discov Immunol. 2024; 3(1):kyae002.

PMID: 38405398 PMC: 10883678. DOI: 10.1093/discim/kyae002.

Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral CD103CD11b dendritic cell population.

Stellas D, Karaliota S, Stravokefalou V, Angel M, Nagy B, Goldfarbmuren K Cell Rep. 2023; 42(5):112501.

PMID: 37178117 PMC: 10758290. DOI: 10.1016/j.celrep.2023.112501.

References

Stoklasek T, Schluns K, Lefrancois L . Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006; 177(9):6072-80. PMC: 2847275. DOI: 10.4049/jimmunol.177.9.6072. View

Rubinstein M, Kovar M, Purton J, Cho J, Boyman O, Surh C . Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006; 103(24):9166-71. PMC: 1482584. DOI: 10.1073/pnas.0600240103. View

Dubois S, Mariner J, Waldmann T, Tagaya Y . IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002; 17(5):537-47. DOI: 10.1016/s1074-7613(02)00429-6. View

Duitman E, Orinska Z, Bulanova E, Paus R, Bulfone-Paus S . How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha. Mol Cell Biol. 2008; 28(15):4851-61. PMC: 2493373. DOI: 10.1128/MCB.02178-07. View

Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C . Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2007; 283(7):4189-99. DOI: 10.1074/jbc.M705725200. View

Sandau M, Schluns K, Lefrancois L, Jameson S . Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J Immunol. 2004; 173(11):6537-41. DOI: 10.4049/jimmunol.173.11.6537. View

Orinska Z, Maurer M, Mirghomizadeh F, Bulanova E, Metz M, Nashkevich N . IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med. 2007; 13(8):927-34. DOI: 10.1038/nm1615. View

Dubois S, Patel H, Zhang M, Waldmann T, Muller J . Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol. 2008; 180(4):2099-106. DOI: 10.4049/jimmunol.180.4.2099. View

Gaggero A, Azzarone B, Andrei C, Mishal Z, Meazza R, Zappia E . Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms. Eur J Immunol. 1999; 29(4):1265-74. DOI: 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V. View

10.

Kutzler M, Robinson T, Chattergoon M, Choo D, Choo A, Choe P . Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol. 2005; 175(1):112-23. DOI: 10.4049/jimmunol.175.1.112. View

11.

Bamford R, DeFilippis A, Azimi N, Kurys G, Waldmann T . The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J Immunol. 1998; 160(9):4418-26. View

12.

Lodolce J, Burkett P, Boone D, Chien M, Ma A . T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J Exp Med. 2001; 194(8):1187-94. PMC: 2193508. DOI: 10.1084/jem.194.8.1187. View

13.

Zolotukhin A, Tan W, Bear J, Smulevitch S, Felber B . U2AF participates in the binding of TAP (NXF1) to mRNA. J Biol Chem. 2001; 277(6):3935-42. DOI: 10.1074/jbc.M107598200. View

14.

Stauber R, Gaitanaris G, Pavlakis G . Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm. Virology. 1995; 213(2):439-49. DOI: 10.1006/viro.1995.0016. View

15.

Koka R, Burkett P, Chien M, Chai S, Chan F, Lodolce J . Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med. 2003; 197(8):977-84. PMC: 2193874. DOI: 10.1084/jem.20021836. View

16.

Tagaya Y, Kurys G, Thies T, Losi J, Azimi N, Hanover J . Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc Natl Acad Sci U S A. 1998; 94(26):14444-9. PMC: 25016. DOI: 10.1073/pnas.94.26.14444. View

17.

Bulanova E, Budagian V, Orinska Z, Krause H, Paus R, Bulfone-Paus S . Mast cells express novel functional IL-15 receptor alpha isoforms. J Immunol. 2003; 170(10):5045-55. DOI: 10.4049/jimmunol.170.10.5045. View

18.

Schluns K, Klonowski K, Lefrancois L . Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells. Blood. 2003; 103(3):988-94. DOI: 10.1182/blood-2003-08-2814. View

19.

Zambello R, Facco M, Trentin L, Sancetta R, Tassinari C, Perin A . Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997; 89(1):201-11. View

20.

Tagaya Y, Bamford R, DeFilippis A, Waldmann T . IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996; 4(4):329-36. DOI: 10.1016/s1074-7613(00)80246-0. View